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Inherited disorders of iron metabolism. Recent molecular stud- The first documentation of a genetic origin of iron
ies have resulted in the identification of genetic alterations overload dates back to the middle 1970s, when Simon
underlying hereditary disorders of iron metabolism. One exam- et al described an association of hemochromatosis withple is the discovery of the HFE gene that is mutated in patients
the HLA-A3 and HLA-B14 gene locus on the short armsuffering from hereditary hemochromatosis. This autosomal
of chromosome 6 [1]. However, 20 more years wererecessive disorder has an estimated carrier frequency that var-
ies between 0.07 and 0.13, thus representing one of the most necessary to uncover the genetic defect underlying a
common genetically determined metabolic disorders. The iden- disease that was for a long time known as “bronze diabe-
tification of the hemochromatosis mutations has encouraged tes” or “idiopathic hemochromatosis.” In 1996, Feder etefforts to investigate other conditions with iron overload for
al cloned the HFE gene, which was shown to be mutateda putative interaction with these genetic variants. Few data are
in patients with hereditary hemochromatosis [2]. Thealready available suggesting, for example, that iron overload
in patients with sporadic porphyria cutanea tarda is associated identification of the mutations resulting in one of the
with mutations in the hereditary hemochromatosis gene. How- most common metabolic diseases (at least in populations
ever, it is obvious that disorders of iron metabolism have a
of European origin) has opened an exciting avenue tomultifactorial pathogenesis, including environmental and ge-
study gene–environment interactions affecting the indi-netic factors. Thus, many questions remain to be answered
about whether a genetic predisposition exists for development vidual risk of iron overload.
of various iron-loading or iron-deficiency phenotypes. This re-
view focuses on the most recent advances in the field of heredi-
tary disorders of iron metabolism and discusses their potential HEREDITARY HEMOCHROMATOSIS
implications for nephrologists.
Background and clinical presentation
Hereditary hemochromatosis is an autosomal reces-
sive metabolic disorder with a prevalence ranging fromDisorders of iron metabolism encompass a heteroge-
0.05% in Finland to 1.2% in Australia [3]. The estimatedneous group of diseases with diverse clinical manifesta-
carrier frequency varies between 0.07 and 0.13 [4, 5].tions, ranging from asymptomatic iron deficiency to se-
Genetic hemochromatosis is characterized by the ab-vere iron overload, which can be fatal if untreated. An
sorption of more iron than required. As the years pass,increased interest in the genetics of iron metabolism has
storage iron is accumulating, resulting in the depositionresulted in the identification of monogenic disorders and
of hemosiderin in various tissues. Once toxic concentra-gene variants that are associated with iron overload.
tions are reached, the resulting damage to organs is oftenBefore embarking on genetics, it is necessary to consider
irreversible. Thus, every effort is mandatory to identifythat the clinical presentation of hereditary disorders of
patients with hereditary hemochromatosis before theiron metabolism is strongly influenced by environmental
full-blown disease develops.determinants. It is obvious that age, gender, and nutri-
tional factors play an important role in the development Because of the lingering course of the disease, the
of iron overload or iron deficiency. For example, if a great majority of patients with manifest hereditary
diet contains little available iron and iron deficiency is hemochromatosis are 40 to 60 years old at time of diagno-
common in a population group, iron overload will be sis, although even much younger patients may present
rarely found, even when a predisposing iron-loading al- with clinical symptoms [6]. At time of diagnosis, the
lele is highly prevalent. intestinal absorption of iron is usually within the normal
range, but considering the enlarged iron stores, absorp-
tion is actually inappropriately high. As a first conse-Key words: genetics, heredity, idiopathic hemochromatosis, porphyria,
quence, plasma iron concentrations and transferrin satu-sideroblastic anemias, African iron overload, hyperferritinemia, micro-
cytic anemia, end-stage renal disease. ration are elevated before the iron stores increase.
Thereafter, plasma ferritin concentrations begin to rise 1999 by the International Society of Nephrology
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because of the deposition of surplus iron in the form of in heterozygotes is moderately increased with little or
no increase in iron stores. Thus, an extensive body ofhemosiderin predominantly in the liver and the pancreas,
but also in the skin, adrenal glands, heart, stomach, thy- studies were done to find the iron-loading gene responsi-
ble for development of hereditary hemochromatosis.roid, spleen, and kidneys.
For a long time, the diagnosis of hereditary hemochro- Based on the observation that patients with genetic
hemochromatosis showed an increased frequency of thematosis has relied on laboratory indices of iron metabo-
lism, HLA typing, liver biopsies, and clinical symptoms HLA-A3 allele [9] and from studies of b2-microglobulin–
deficient mice [10], it was suggested that the hereditary(for example, hepatomegaly associated with abdominal
pain, diabetes mellitus, arthritis, diminished sexual func- hemochromatosis gene might be linked to the HLA gene
locus. Using an impressive positional cloning approach,tion, infections, skin pigmentation, xerosis cutis, arrhyth-
mias, cardiac failure) [6, 7]. The clinical manifestations, Feder et al could recently identify a gene with similarity
to HLA class I genes that was therefore initially desig-however, are heterogeneous, thus rendering establish-
ment of the definitive diagnosis difficult. Furthermore, nated “HLA-H” [2]. However, HLA-H had already been
used in 1990 by Chorney et al, who described a pseudo-it has to be remembered that the classic “bronzed diabe-
tes” triad of skin pigmentation, diabetes, and cirrhosis gene located between HLA-B and HLA-A, which is
clearly different from Feder’s HLA-H [11]. Accordingis only rarely seen. The most common complaints of
patients with noncirrhotic hereditary hemochromatosis to the HUGO Genome Database Nomenclature Com-
mittee, the gene is now renamed as “HFE” [12, 13].are weakness and lethargy (73% of patients), joint pain
(45%), abdominal pain (39%), loss of potency (27%), The HFE gene is localized about 4.0 megabases telo-
meric to HLA-A. The cDNA is 1029 base pairs long,amenorrhea (17%), and dyspnea (10%) [7]. Thus, it is
conceivable that hereditary hemochromatosis is fre- encoding a polypeptide of 343 amino acid residues. HFE
is highly homologous to major histocompatibility com-quently unrecognized. The early diagnosis, however, is
essential, because a simple, cheap, and effective therapy plex (MHC) class I molecules and shows all their struc-
tural hallmarks including three extracellular domains(phlebotomy) is available for depletion of surplus iron
to prevent serious morbidity and mortality. (designated a1, a2, and a3, respectively). It contains four
cysteine residues forming disulfide bridges that provideThe diagnosis of hereditary hemochromatosis impli-
cates the exclusion of other common causes of secondary the conformation required for the noncovalent interac-
tion of MHC class I molecules with b2-microglobuliniron overload (such as sideroblastic anemia, chronic he-
molysis, porphyria cutanea tarda, chronic hepatitis C, and the correct cell surface expression. In patients with
hereditary hemochromatosis, this gene has been shownsteatohepatitis, or chronic alcoholism) [7]. Transferrin
saturations above 50% are suggestive of hereditary to be mutated [2]. The most prevalent mutation was
identified at nucleotide position 845 (transition of G tohemochromatosis and should be repeated in a morning
fasting specimen [6, 7]. However, transferrin saturations A), which results in a cysteine to tyrosine substitution
at amino acid 282 (Cys282Tyr). This missense mutation ismay be lower during infections, masking the presence
of iron overload. The ferritin concentrations found in localized at a highly conserved residue of the a3 domain
involved in the intramolecular disulfide bridging in MHCpatients with hereditary hemochromatosis may range
from initially normal to several thousands micrograms class I proteins, resulting in the elimination of cell surface
presentation of the encoded protein. This mutation wasper liter. Once hereditary hemochromatosis is suspected,
it is advisable to perform a needle biopsy of the liver to detectable on 85.7% of chromosomes of patients with
established hereditary hemochromatosis and in 3.2% ofdetermine the iron content (Perl stain, where typically
stainable iron is in at least 75% of hepatocytes and some- control chromosomes with an estimated carrier fre-
quency of 0.064 [2]. Among the 178 patients with heredi-what less iron in the Kupffer cells; a hepatic iron index
of more than 1.9 in homozygous hereditary hemochro- tary hemochromatosis, 148 were homozygotes (83.1%),
9 individuals were heterozygous (5.1%), whereas 21 pa-matosis patients) and to define the degree of tissue dam-
age (fibrosis, cirrhosis, hepatocellular carcinoma), which tients were homozygous for the normal allele (11.8%;
Table 1). Detailed analysis of these data in a heterogene-is of important prognostic value [7, 8].
ity model revealed that there were more heterozygous
Genetics of hereditary hemochromatosis patients than expected from the model, thus suggesting
the presence of an additional mutation in heterozygousDuring the past few decades, the early diagnosis of
hereditary hemochromatosis was severely hampered by patients.
the lack of a direct diagnostic test. In particular, the clear
A second gene defect in patients with hereditarydistinction of heterozygotes from homozygous hemo-
hemochromatosis?chromatosis patients was difficult, and serial observations
over a number of years were often necessary to identify Efforts to find an additional genetic variant in patients
with hereditary hemochromatosis in whom the Cys282Tyrthe true carrier state. Usually, the transferrin saturation
Fo¨dinger and Sunder-Plassmann: Genetics of iron metabolismS-24
Table 1. Geographic variation of the Cys282Tyr HFE allele among patients with established hereditary hemochromatosis and healthy controls
Cys282Tyr (nucleotide 845:
Total CompoundG to A transition) % of cases
number heterozygotes Allele frequency Carrier Geographic
of cases A/A A/G G/G % of cases patients (controls) frequency area Reference
178 83.1 0.6 11.8 4.5 0.85 (0.032) 0.064 U.S.A. [2]
416 85.1 0.7 9.6 4.6 0.88 (0.057) 0.109 U.S.A. [14]
75 64.0 2.7 26.6 6.7 0.69 (0.010) 0.020 Italy [33]
65 90.8 0.0 4.6 4.6 0.93 (0.029) 0.058 France [32]
147 82.3 1.4 10.9 5.4 0.86 (0.075) 0.150 U.S.A [29]
112 100.0 0.0 0.0 0.0 1.00 (n.t.) — Australia [31]
94 72.3 4.3 19.1 4.3 0.77 (0.042) 0.084 France [34]
5 0.0 0.0 100.0 0.0 0.00 (0.0018) 0.0034 China [35]
20 100.0 0.0 0.0 0.0 1.0 (n.t.) — New Zealand [36]
188 63.8 5.8 25.0 5.3 0.86 (n.t.) 0.111 Italy [38]
Abbreviation is n.t., not tested.
substitution was only present on one allele resulted in Interestingly, Crawford et al reported that male indi-
viduals with two copies of the ancestral HFE mutationthe identification of a mutation that was in complete
linkage disequilibrium with the Cys282Tyr mutation present with more severe disease than those with only
one copy or none [21]. However, others described that(that is, no chromosome carried both mutations). This
mutation was localized at nucleotide position 187 in the not all paternally-transmitted mutations are associated
with the ancestral HLA-A3 haplotype [22] and do nota1 domain of HFE (exchange of C by G) and led to a
histidine to aspartic acid substitution at amino acid 63 present with severe hemochromatosis. Thus, additional
studies are required to find out whether male hemochro-(His63Asp), which, in contrast to Cys282Tyr, has no
effect on b2-microglobulin association [2]. The mutation matosis patients showing the ancestral haplotype are in-
deed at risk for severe hemochromatosis.was identified in eight of nine chromosomes of patients
that were heterozygous for the Cys282Tyr substitution
Potential function of the HFE gene product(88.9%), in contrast to the allele frequency of 0.17 in
The mechanism of how the HFE gene contributes tohealthy individuals. Only one patient was homozygous
iron overload is a matter of current investigation. It isfor the His63Asp allele. Therefore, it seems likely that
expressed in most of the tissues (length of the mRNAhomozygosity for the His63Asp mutation is not associ-
is 4 kb) that are affected by hereditary hemochromatosis,ated with hereditary hemochromatosis. Conversely, this
particularly in the small intestine and the liver [2]. Immu-mutation was enriched in frequency in hereditary hem-
nohistochemical studies using an antibody against theochromatosis patients heterozygous for the Cys282Tyr
C-terminal peptide demonstrated a characteristic stain-substitution (compound heterozygotes; Table 1). Thus,
ing pattern for the HFE protein in the small intestine thatthe His63Asp mutation seems to cause hereditary hemo-
is unique compared with other segments of the intestinalchromatosis when inherited together with the Cys282Tyr
tract [23]. The first evidence that an MHC class I-likemutation [2, 14].
molecule is involved in iron homeostasis came from
Ancestral haplotype, founder effect, and hypothesis on b2-microglobulin knockout mice, which fail to limit intes-
an evolutionary selection process of HFE tinal iron absorption in the presence of iron overload.
Typically, these mice show progressive hepatic iron over-From several studies, it seems likely that hereditary
hemochromatosis has spread by multiplication of a founder load, which resembles that in hereditary hemochro-
matosis [24]. The underlying mechanism has been re-mutation characterized by an HLA-A3–associated an-
cestral haplotype [15–19]. It is possible that in the past, cently identified as an increase in mucosal iron uptake
and enhanced transfer of iron in the plasma [25].heterozygotes had a selection advantage because they
absorbed more dietary iron and were, therefore, more To characterize the potential function of the HFE
protein, HFE gene knockout mice have been recentlyprotected against iron deficiency [14, 20]. Accumulation
of body iron reserves probably improved survival during analyzed [26]. In these mice, a significantly elevated fast-
ing transferrin saturation and a hepatic iron concentra-infancy, childhood, and pregnancy. As a consequence,
the frequency of the mutation gradually increased. The tion that was eightfold higher compared with wild-type
littermates have been observed [26]. Another study dem-selection against homozygous subjects is minimal, as the
disease usually exerts clinical symptoms after the repro- onstrated that the wild-type and the His63Asp HFE gene
product form stable complexes with the transferrin re-ductive period, at a time when such patients have trans-
mitted the mutated HFE gene to their offspring. ceptor, whereas the His282Tyr mutation almost com-
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pletely abolished this association [27]. Moreover, it has clinical manifestation. According to the origin of exces-
been shown that binding of HFE to the transferrin recep- sive production of porphyrin precursors and/or porphy-
tor is pH dependent [28]. Thus, further evidence is accu- rins, hereditary porphyrias can be classified as hepatic
mulating, indicating that HFE is involved in the regula- or erythropoietic [40]. One example for a hepatic type
tion of iron homeostasis. of porphyrias is porphyria cutanea tarda, which may
occur in sporadic (type I) or familial (type II) forms.
Clinical relevance of genetic testing
Familial porphyria cutanea tarda is an autosomal domi-for hemochromatosis
nant trait that is characterized by a decreased activity
The recent discovery of the genetic defect underlying of the enzyme uroporphyrinogen decarboxylase in all
hereditary hemochromatosis has provided a novel tool tissues, whereas in sporadic porphyria cutanea tarda,
that allows for the screening of patients for the presence uroporphyrinogen decarboxylase activity is normal in
of hereditary hemochromatosis. A number of studies on erythrocytes and only decreased in the liver.
patients with established hereditary hemochromatosis The main clinical symptom in both types of porphyria
of different ethnic origin almost immediately provided cutanea tarda is the cutaneous photosensitivity with skin
further evidence that the Cys282Tyr substitution is asso-
lesions following sun exposure. Usually, skin manifesta-ciated with hereditary hemochromatosis, irrespective of
tions (small white milia, fluid-filled vesicles, and bullae)the patient’s haplotype [14, 29–39]. The frequency of
develop on sun-exposed regions, for example, the face,homozygosity for Cys282Tyr in these different popula-
legs, feet, forearms, and the dorsa of the hands. Further-tion groups ranged between 0.0 in China [35] and 1.0 in
more, increased pigmentation, hirsutism, and infectionsAustralia [31] and New Zealand [36], which was probably
of the skin lesions may be present. Another importantdue to differing clinical criteria for diagnosis of heredi-
feature of porphyria cutanea tarda is the presence oftary hemochromatosis (Table 1). Another possible ex-
hepatic siderosis together with inappropriately high in-planation is that genetic hemochromatosis is not as ho-
testinal iron absorption [41]. As a result of the decreasedmogenous as initially supposed [37]. The prevalence of
or abolished activity of uroporphyrinogen decarboxyl-compound heterozygosity for the Cys282Tyr and the
ase, porphyrins are increased in the liver, plasma, urine,His63Asp allele was 4.5%, 4.6%, and 5.4% in U.S. citi-
and stool. The urinary porphyrins usually consist of uro-zens [2, 14, 29], 4.3% and 4.6% in France [32, 34], and
porphyrin and 7-carboxylate porphyrin, whereas fecal5.3% and 6.7% in Italy [33, 38], whereas no compound
porphyrins are isocoproporphyrins. Thus, the character-heterozygous individual was identified among Australian
and Chinese individuals and in patients from New istics leading to the diagnosis of porphyria cutanea tarda
Zealand with manifest genetic hemochromatosis [31, 35, are the photosensitive skin and elevated uroporphyrin
36]. The penetrance of the compound heterozygous state levels in the urine [40]. The causative defect underlying
seems to be only approximately 1%, which means that the decreased hepatic uroporphyrinogen decarboxylase
only 1 of 100 affected individuals will develop symptom- activity in patients with sporadic porphyria cutanea tarda
atic hemochromatosis [14]. is unknown. Some early authors suggested the presence
A specific DNA-based test is now available that allows of a recessive genetic disorder that might precipitate in
early detection of hereditary hemochromatosis and pre- the presence of an additional acquired condition [42]. It
vention of organ damage. Hence, it is possible to investi- is well established that alcohol abuse, estrogen intake,
gate asymptomatic relatives to find out which alleles liver damage, various chemicals (such as dioxin), and
they have inherited. However, it has to be taken into excess of iron are exogenous factors that contribute to
consideration that the presence of two Cys282Tyr- the pathogenesis of porphyria cutanea tarda.
mutated alleles does not always result in the phenotypic
disease expression. It has been recently observed that Potential role of HFE in sporadic porphyria
32.7% of Cys282Tyr-homozygous females and 6.7% of cutanea tarda
Cys282Tyr-homozygous males do not show iron over-
The cause of the commonly observed hepatic ironload [39]. Nevertheless, the identification of the HFE
overload in patients with sporadic porphyria cutaneamutations makes it possible to assess the role of the HFE
tarda has remained an enigma for a long time. Iron doesgene in other conditions with iron overload, as discussed
not directly inhibit uroporphyrinogen decarboxylase, butin more detail later here.
is required for inactivation of this enzyme [43]. Interest-
ingly, repeated phlebotomy can produce remissions in
SPORADIC PORPHYRIA CUTANEA TARDA almost all patients, thus suggesting involvement of a
AND MUTATION (Cys282Tyr) IN THE hemochromatosis-associated factor in hepatocellular sid-
HFE GENE erosis. In 1985, a pedigree study conducted by Kushner
Background and clinical presentation et al supported the idea of an association of a HLA-
linked hereditary hemochromatosis allele in the pheno-Porphyrias represent a group of various inherited dis-
orders of heme biosynthesis with remarkable different typic expression of porphyria cutanea tarda [42]. Further
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evidence was provided more recently by Fargion et al, ERYTHROPOIETIC PROTOPORPHYRIA AND
who demonstrated a greater prevalence of the HLA-A3 MUTATION IN THE FERROCHELATASE GENE
allele in individuals with iron overload than in those Erythropoietic protoporphyria is another example of
without [44]. Therefore, most recently, the question an inherited disorder of heme biosynthesis that is clini-
arose whether the Cys282Tyr HFE gene mutation might cally characterized by photosensitivity of the skin [40].
be involved in iron overload of porphyria cutanea tarda. It represents the most common form of erythropoietic
Indeed, in February 1997, Roberts et al reported an porphyria. Most likely, this type of porphyria is inherited
increased frequency of the hemochromatosis Cys282Tyr as an autosomal dominant trait [49, 50], although data
mutation in patients with sporadic porphyria cutanea are available in the literature raising the possibility of
tarda [45]. The Cys282Tyr mutation occurred in 43.9% an autosomal recessive mode of inheritance [51].
of their patients versus 10.9% of controls. Eight of 41 The main biochemical characteristic in patients with
patients were heterozygous carriers of the mutation erythropoietic protoporphyria is the accumulation of
(19.5%). Seven of 41 patients (17.1%) showed a homozy- protoporphyrin IX in erythrocytes, plasma, the liver, and
gous mutation, and three patients (7.3%) were compound feces resulting from a decreased activity of the enzyme
heterozygotes for both the Cys282Tyr and the His63Asp ferrochelatase [49]. Ferrochelatase is the final enzyme
mutation. The frequency of the His63Asp mutation did of the heme biosynthesis pathway, which catalyzes the
not differ between patients and controls. These data were insertion of ferrous iron into protoporphyrin IX to form
immediately confirmed by a Dutch group [46]. In this heme. In erythropoietic protoporphyria, the gene coding
study, Santos, Clevers and Marx found an allele fre- for ferrochelatase has been shown to be mutated. In
quency of 0.47 for patients with porphyria cutanea tarda 1992, Nakahashi et al have described a point mutation
versus 0.09 for healthy blood donors and 0.83 in patients (C to T) near the acceptor site of intron 1 responsible
with hereditary hemochromatosis. Five of 15 patients for an abnormal post-transcriptional splicing of ferro-
(33.3%) were heterozygous for either the Cys282Tyr or chelatase mRNA [50]. This report of a heterozygous
the His63Asp substitution, and 6 of 15 subjects (40%) mutation indicates that erythropoietic protoporphyria
were homozygous for one of these mutations. In this in this study was inherited as an autosomal dominant
study, two of 15 patients (13.3%) with porphyria cutanea
disorder and represents the first observation of an unsta-
tarda were identified as compound heterozygotes for
ble ferrochelatase mRNA, explaining the decreased en-
both HFE alleles [46]. More recently, an Italian study
zyme activity commonly observed in patients with eryth-in 68 male patients with sporadic porphyria cutanea tarda
ropoietic protoporphyria.could not confirm the association of porphyria cutanea
tarda with the Cys282Tyr HFE allele [47]. Surprisingly,
the authors observed an increased frequency of the MUTATION (Cys282Tyr) IN THE HFE GENE
His63Asp substitution in their patients, which was, how- AND PYRIDOXINE-RESPONSIVE
ever, not related to the iron status. SIDEROBLASTIC ANEMIA
An important result of the study by Roberts et al Background and clinical presentation
is the high prevalence of 17.1% for the homozygous
Sideroblastic anemias are a heterogeneous group ofCys282Tyr hemochromatosis mutation in their patients
hypoproliferative anemias showing ringed sideroblastswith porphyria cutanea tarda [45]. This observation is
in bone marrow aspirates [40]. These sideroblasts areclinically relevant, as it appears likely that patients even
erythroid precursors containing iron-loaden mitochon-older than 60 years may be homozygous for this mutation
dria that encircle the nucleus, accounting for the ringedwithout the development of manifest hemochromatosis.
appearance. Sideroblastic anemias can be classified asAnother interesting observation of this group was that
inherited or acquired, where the former is usually trans-approximately 37% of British patients with sporadic por-
mitted as an X-chromosomal–linked trait. Acquired sid-phyria cutanea tarda carry at least one hemochromatosis
eroblastic anemias are designated primary (myelodys-gene, compared with 10% of the general population [48].
plastic syndrome) or secondary, following exposition ofFrom these studies mentioned earlier in this article, it
the bone marrow to toxic agents (alcohol, various drugsseems likely that a heterozygous or homozygous transi-
such as isoniacid or chloramphenicol), in the course oftion of G to A at nucleotide position 845 of the HFE
infection or chronic inflammation.gene is a susceptibility factor for porphyria cutanea tarda.
The diagnosis of sideroblastic anemia is usually estab-Therefore, patients with porphyria cutanea tarda should
lished by morphological examination of Prussian-blue–be screened for hereditary hemochromatosis to (a) find
stained bone marrow smears. The secondary and theout whether mutations in the HFE gene are indeed asso-
X-linked anemias are frequently dimorphic, that is, aciated with porphyria cutanea tarda and (b) enable ade-
coexistence of hypochromic microcytic erythrocytes andquate therapeutic intervention, as has been recently sug-
gested [46]. normochromic cells. Therapeutic strategies include trans-
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fusions for maintenance of hematocrit, application of sulting in liver damage (cirrhosis, hepatoma), diabetes
mellitus, and cardiac failure.pyridoxine (X-linked variants), and removal of the toxic
Although the increased environmental iron intake wasagent [40].
considered to represent the only source of the increased
Variation of iron overload in sideroblastic anemia: iron absorption, it was hypothesized early that genetic
Involvement of genetic factors? factors may exist explaining the observation that not all
drinkers of traditional beer develop iron overload [54].The ineffective erythropoiesis in sideroblastic anemia
In 1992, Gordeuk et al performed a large pedigree analy-leads to various degrees of accumulation of unneeded
sis that included 236 members of 36 African familiesiron. Interestingly, although anemia is present, X-linked
who had index patients with evidence of iron overload.sideroblastic anemia has been reported to improve fol-
Using likelihood analysis, they clearly demonstrated alowing careful episodes of phlebotomy to remove the
genetic influence coupled with an effect of dietary ironexcess iron [40, 52].
intake on transferrin saturation and unsaturated iron-The reasons for the diverging amounts of accumulat-
binding capacity [55]. Further evidence for a geneticing iron in sideroblastic anemia is only partially under-
influence of iron overload has been recently reported instood. Recently, Yaouanq et al observed discordant de-
Zimbabweans and South Africans [56].grees of iron overload in two brothers with established
This report suggests the presence of an interactionX-linked sideroblastic anemia. One of these brothers,
between an iron-loading gene and the amount of dietaryaged 59 years, had ferritin concentrations as high as 3500
iron intake in Africans. Interestingly, this study couldmg/liter and suffered from hepatic cirrhosis, whereas the
exclude linkage of this putative gene to HLA. Thus, itother brother (61 years old) had a serum ferritin of only
is unlikely that the described HFE mutations are respon-874 mg/liter with only mild clinical symptoms (arthral-
sible for iron overload in every African suffering fromgias). Based on the assumption that mutations in the
hereditary iron overload. More recently, the presence ofHFE gene might represent a risk factor for increased
iron overload has also been described in African Ameri-absorption of iron, the authors hypothesized that these
cans [57–59]. These findings might gain clinical impor-brothers could be different with respect to the Cys282Tyr
tance with the consequence of early screening programs
and/or the His63Asp mutation of the HFE gene. In fact,
for iron overload in Africans.
the brother with the higher iron stores was compound
heterozygous for the Cys282Tyr and the His63Asp muta-
HEREDITARY HYPERFERRITINEMIA–tion. Conversely, his brother was negative for both HFE
CATARACT SYNDROMEmutations [52].
Background and clinical presentation
Clinical relevance
The hereditary hyperferritinemia–cataract syndrome
Compound heterozygosity for the above-mentioned is a new autosomal dominant disease initially described
mutations in the HFE gene is established as a risk factor by two groups in 1995 [60, 61]. This disorder is character-
for increased absorption of iron [2, 14], and approxi- ized by the marked elevation of serum ferritin levels and
mately 1% of these patients develop manifest hemochro- bilateral cataract, in the absence of laboratory indices
matosis [14]. Thus, it is likely that the compound hetero- of iron overload (normal serum iron and transferrin satu-
zygous state of the brother with more severe iron ration) or inflammation.
overload accounted for his larger iron stores. This initial Measurement of serum ferritin is clinically valuable
report strongly suggests a role of HFE gene mutations for determination of the iron stores. However, several
in the clinical presentation of sideroblastic anemia. Test- clinical situations exist in which ferritin levels are inap-
ing for this mutation may improve the management of propriately high with respect to the true body iron stores.
sideroblastic anemia and provides a basis for a rapid Besides the rare hereditary hyperferritinemia–cataract
decided effective treatment strategy (phlebotomy). syndrome, raised ferritin levels may occur during in-
flammatory reactions, in the course of hepatitic liver
damage, and in association with neoplasms [20, 62]. Fer-
AFRICAN IRON OVERLOAD: ritin is composed of a protein shell that surrounds the
A GENE–ENVIRONMENT INTERACTION? iron core. The apoprotein shell is build up of 24 subunits
In sub-Saharan Africa, iron overload is commonly ob- that are designated H (heavy, 21 kDa, 182 amino acid
served and thought to result from an increased iron in- residues), L (light, 19 kDa, 174 amino acid residues),
take by the population consuming large quantities of a and G (glycosylated, 23 kDa), respectively [63, 64]. Inter-
fermented beer that is home brewed in steel drums [53]. estingly, serum ferritin contains almost exclusively L and
Surplus iron accumulates in these patients in quantities G subunits. The genes coding for the H and L chains
are localized on chromosomes 11 and 19 (Table 2),comparable to hereditary hemochromatosis, thus re-
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Table 2. Chromosomal localization and function of various genes coding for proteins involved in iron metabolism
Chromosomal
Gene localization Characterics of encoded protein Function of the gene product
HFE 6p21.3 Similarity to HLA class I molecules Regulation of iron homeostasis
Transferrin 3q21–3q25 Single-chain glycoprotein Iron transport
Transferrin receptor 3q26.2 Transmembrane glycoprotein dimer Endocytosis of ferric transferrin
H subunit of ferritin 11q13 Cylindrical 44 kDa protein Iron storage (mainly acidic ferritins)
L subunit of ferritin 19q13.3 Cylindrical 44 kDa protein Iron storage (mainly basic ferritins)
Iron-responsive element (IRE ) 9 Specific RNA structure in ferritin mRNAs Iron-dependent translational control of
ferritin mRNA
Iron regulatory protein (IRP ) 9 Cytoplasmic binding protein with 30% Inhibits translation of ferritin and degradation of
homology to mitochondrial aconitase transferrin receptor mRNA
Ferrochelatase 18q21.3 Polypeptide with enzyme activity Catalyzes insertion of ferrous iron into
protoporphyrin IX to form heme
Table 3. Hereditary hyperferritinemia-cataract syndrome: Mutations in the L-ferritin gene and corresponding ferritin levels in affected patients
Ferritin levels
Localization of mutation Gene defect lg/liter Degree of cataract Reference
IRE loop, nt 140a Heterozygous A to G substitution 1160–1680 Severe [60]
IRE loop, nt 140a Heterozygous A to G substitution 780–1000 Severe [70]
IRE loop, nt 140a Heterozygous A to G substitution 902–1452 Severe [73]
IRE loop, nt 141 Heterozygous G to C substitution 950–2259 Severe [68]
IRE loop, nt 139 Heterozygous C to T substitution 1389 Severe [74]
IRE bulge, nt 132 Heterozygous G to A substitution 950–1890 Mild [71]
IRE bulge, nt 132 Heterozygous G to T substitution 1200–2264 Range from absent to severe [72]
IRE lower stem, nt 132 and nt 118 Double point mutation, T to G substitution
and C to T substitution 366–635 Asymptomatic [71]
IRE stem loop, from nt 110 to 138 Deletion of 29 base pairs 763–1822 Severe [69]
IRE upper stem, nt 136 Heterozygous C to A substitution 1020 Severe [74]
Abbreviations are: IRE, iron-responsive element; nt, nucleotide; the numbers (110, 118, 122, 132, 136, 138, 139, 140, 141) represent the nucleotide position
in the 59 untranslated region of L-ferritin where 11 is the start of transcription.
a These mutations are identical and localized at the same nucleotide position
whereas the G subunit is likely to represent a post-trans- interaction between the ferritin mRNA and the cyto-
plasmic IRPs. Thus, mutations or deletions in this motiflational modified L chain [64]. The human ferritin syn-
thesis is finely regulated by iron through the interaction result in a profound reduction or complete deletion of
the IRE/IRP binding, which normally controls overex-of iron regulatory proteins (IRPs) and an iron responsive
element (IRE) located within the 59 noncoding region pression of ferritin by blocking its translation. The muta-
tions described outside the conserved CAGUG sequenceof the ferritin mRNA [65–67].
include single-point mutations in the IRE bulge [71, 72]
Genetics of hereditary hyperferritinemia–cataract and the upper stem [74], one double-point and one-single
syndrome point mutation in the IRE lower stem [71], and a deletion
of 29 base pairs in the IRE stem loop [69].To date, nine different mutations (including one dou-
ble-point mutation) have been identified in a total of Interestingly, although ferritin is widely expressed in
various tissues, the phenotype observed among patients11 families with hereditary hyperferritinemia–cataract
syndrome [60, 68–74]. They all were initially reported with mutations in the L-ferritin IRE is limited to a single
organ and serum hyperferritinemia. The reason for thisindependently in different towns of France and Italy, rang-
ing from Paris [60, 72] and Montpellier [70] to Verona moderate phenotype (nuclear cataract) is unclear. It has
been shown that canine lens epithelial cells synthesize[68], Foggia [69], and Pavia [71], and showed different
patterns in the phenotypic expression of the disease (Table ferritin, a process that is regulated by iron [75]. Thus, it
is conceivable that the excessively synthesized L-ferritin3). More recently, three families with inherited hyperfer-
ritinemia have been described in England [73, 74]. Inter- in hereditary hyperferritinemia precipitates early in lens
opacity.estingly, the great majority of the genetic aberrations in
affected members of these families were identified in the
Clinical relevance of hereditary hyperferritinemiaL-ferritin gene closely clustered in the CAGUG motif
of the IRE. This highly conserved nucleotide sequence The independent description of the hyperferritinemia–
cataract syndrome in Italy, France, and England suggestsforms the IRE loop, which mediates the high-affinity
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that the syndrome may not be so sporadic as initially a candidate gene that is involved in iron uptake. These
believed. From these studies, it is likely that this syndrome breakthroughs have now opened the possibility to assess
does not result form a unique mutational origin, but the role of this iron transporter in patients with heredi-
appears to be a unique phenotype with heterogeneous tary hemochromatosis and to illuminate its possible in-
mutations. Therefore, it is possible that other affected teraction with HFE.
families have other mutations in IRE of the L-ferritin
gene.
GENETICS OF IRON METABOLISM:It is to be hoped that in the near future clinicians
IMPLICATIONS FOR NEPHROLOGISTSthink of this new syndrome when facing inexplicably
Iron demand and iron overload in end-stage renalhigh serum ferritin levels in their patients. At this point,
disease patientsit has to be mentioned that even lower ferritin concentra-
tions (approximately 400 mg/liter) can be observed in The discovery of the hereditary hemochromatosis
these patients [71]. Furthermore, it is necessary to ex- gene (HFE) has launched a new era of research into
clude the presence of hereditary hemochromatosis to the regulation of iron metabolism. The finding of the
prevent phlebotomy-induced iron-deficiency anemia on Cys282Tyr and the His63Asp mutation makes it possible
the basis of a mistaken diagnosis. to assess the role of the HFE alleles in various conditions
of iron overload.
Intensive parenteral iron supplementation has evolvedINHERITED MICROCYTIC ANEMIA IN MICE:
to be the most important tool to improve efficacy ofIDENTIFICATION OF NRAMP2 AS AN IRON
erythropoietin therapy for renal anemia [62, 83]. EvenTRANSPORTER GENE
hemodialysis patients without overt iron deficiency rou-Microcytic anemia is commonly observed in humans,
tinely receive parenteral iron during erythropoietin ther-and over one half of the cases are attributed to iron
apy [84]. In contrast, oral iron supplementation is recom-deficiency [76]. However, although rarely seen, micro-
mended for most predialysis and peritoneal dialysiscytic anemia can also present as an inherited disease [77].
patients without iron deficiency (absolute iron deficiencyThe first evidence that anemia might also be genetically
in renal failure patients on erythropoietin therapy is de-determined came from the microcytic mk/mk mouse
fined by ferritin levels of less than 100 mg/liter) [85].model that Bannermann et al described in 1972 [78].
However, iron demand and the degree of iron overloadThese mice suffer from severe microcytic hypochromic
vary between individual patients receiving both erythro-anemia and intestinal iron malabsorption that is unre-
poietin and iron. Besides environmental factors such assponsive to increased dietary iron. A similar block is
chronic hepatitis, diet, or regular blood transfusions, onesuggested to exist in red blood cell precursors because
hypothesis relies on the existence of genetic determi-treatment with parenteral iron does not result in im-
nants that might influence the response to oral iron in-provement of anemia in these mice.
take and the susceptibility for iron overload in patientsAlthough iron deficiency anemia is highly prevalent
under parenteral iron therapy.in the general population, the mechanism by which the
To elucidate whether the response to iron supplemen-body takes up iron from the diet is far from clear. Impor-
tation in patients with end-stage renal disease is alsotant insights into one possible mechanism have emerged
genetically determined, we have screened 396 patientsfrom the recent study by Fleming et al, who demon-
maintained on chronic hemodialysis treatment at fourstrated that the mk gene locus on chromosome 15 of
different Austrian dialysis units for the presence of themk/mk mice is identical with a previously characterized
Cys282Tyr and the His63Asp hereditary hemochro-gene, Nramp2 [79]. In these mice, a G to T transition at
matosis alleles. We found an allele frequency of 0.037a CpG dinucleotide of Nramp2 was identified that re-
for the Cys282Tyr substitution and 0.14 for the His63Aspsulted in a substitution of arginine for glycine at codon
mutation (Table 4). These frequencies correspond with185 [79]. Interestingly, this amino acid alteration has also
observations in healthy subjects without end-stage renalbeen identified in rats and has been shown to disrupt
disease in Austria (R. Maier-Dobersberger, personalthe endosomal iron transport [80]. The characterization
communication) and is in line with the frequencies ob-of these mutations provides the first evidence that
tained in healthy individuals of California (UnitedNramp2 is involved in normal intestinal iron absorption,
States), and France (0.032 and 0.029 for the Cys282Tyrtransport of iron out of the transferrin cycle endosome,
allele; Table 1) [2, 32]. However, the allele frequenciesand utilization of iron in hematopoietic cells [79–81].
observed in hemodialysis patients of the different dialysisIn this context, the recent discovery that the rat iso-
centers in Austria showed great variations, thus pointingform of Nramp2 (DCT1) stimulates iron uptake by ap-
to the need of screening of large patient cohorts to obtainproximately 200-fold in response to iron deficiency has
gained major importance [82]. Thus, Nramp2 represents representative data (Fig. 1 and Table 4). The impact of
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Table 4. Allele frequencies and distribution of the Cys282Tyr and His63Asp HFE alleles
in 396 Austrian hemodialysis patients from four different centers
Cys282Tyr (nucleotide 845 G to A) His63Asp (nucleotide 187 C to G) Compound
Number Cys282Tyr Allele AlleleA/A A/G G/G G/G G/C C/C
of His63Asp frequency frequency
Center cases (%) Cys282Tyr His63Aspnumber of cases (%)
A 267 0 (0.0) 13 (4.9) 246 (92.1) 6 (2.3) 58 (21.7) 201 (75.3) 2 (0.8) 0.026 0.133
B 51 0 (0.0) 6 (11.8) 45 (88.2) 1 (2.0) 9 (17.7) 41 (80.4) 0 (0.0) 0.059 0.108
C 29 0 (0.0) 0 (0.0) 29 (100.0) 2 (6.9) 8 (27.6) 19 (65.5) 0 (0.0) 0.000 0.207
D 49 0 (0.0) 7 (14.3) 41 (83.7) 0 (0.0) 11 (22.5) 37 (75.5) 1 (2.0) 0.086 0.123
Total 396 0 (0.0) 26 (6.6) 361 (91.2) 9 (2.3) 86 (21.7) 298 (75.3) 3 (0.8) 0.037 0.135
porphyria cutanea tarda in dialysis patients is often more
severe than in patients without renal disease. Recombi-
nant erythropoietin is likely to be an effective therapy
to enable therapeutic phlebotomy in such patients be-
cause it can mobilize excess iron stores [90]. In patients
who do not respond to this treatment, renal transplanta-
tion may be beneficial, as has been recently reported [91].
Based on the observation that the Cys282Tyr mutation
in the HFE gene is highly prevalent in patients with
porphyria cutanea tarda [45, 46], it is feasible to speculate
that hemodialysis patients developing porphyria cutanea
tarda are carriers of this mutation. However, no defini-
tive answer is available so far.
Hepatitis and iron overload
Chronic hepatitis is present more often in patients
with end-stage renal disease than in subjects withoutFig. 1. Analysis of the Cys282Tyr (h) and His63Asp ( ) alleles of
the HFE gene in 396 hemodialysis patients. Carrier frequencies were renal disease [92], and is commonly associated with iron
obtained from four different Austrian hemodialysis centers: A, N 5 overload. This finding has raised the interesting question267; B, N 5 51; C, N 5 29; D, N 5 49; Total, N 5 396.
of whether hepatic iron might somehow influence the
way the liver responds to hepatotropic viruses. Consider-
ing the association of the HFE gene mutations with he-
the HFE mutations on the development of iron overload patic iron overload, one may hypothesize about an asso-
in hemodialysis patients is currently under investigation. ciation of the increased incidence of hepatitis with the
iron overload status and hence with the Cys282Tyr and/
Sporadic porphyria cutanea in renal failure patients or His63Asp amino acid substitution of the HFE gene
Chronic hemodialysis treatment may be associated product. This potential interaction deserves further in-
with sporadic porphyria cutanea tarda, which is thought vestigation.
to be due to the ineffective clearance of plasma porphy- The first data about a potential role of the HFE gene
rins through the dialysis membrane and uremia-related mutations in liver disease are already available. Aldersley
decreased activity of the enzyme uroporphyrinogen de- et al have investigated the prevalence of the Cys282Tyr
carboxylase [86–88]. Besides alcohol intake and various hemochromatosis gene mutation in patients with alco-
drugs, iron overload is thought to represent the major holic and cholestatic liver diseases without renal disease
contributing factor resulting in clinically manifest spo- [93], because previous studies demonstrated an iron-
radic porphyria cutanea in these patients. Even in pa- induced aggravation of liver damage in alcoholic liver
tients on chronic ambulatory peritoneal dialysis, por- disease of animals. However, the prevalence of this muta-
phyria cutanea tarda has been rarely observed, for tion was rather low, thus providing initial evidence that
example, in association with administration of phenytoin the Cys282Tyr HFE allele is not a risk factor for the
for seizure disorders [89]. development of alcoholic/cholestatic liver disease.
Iron-induced porphyria cutanea tarda is likely to be
Hyperferritinemia in patients with renal failuredue to the inactivation of uroporphyrinogen decarboxyl-
ase, which is reversible following depletion of surplus Serum ferritin levels normally reflect iron stores in
renal failure patients maintained under iron therapy.iron by phlebotomy. Interestingly, the course of sporadic
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However, increased ferritin levels may not always indi- substitution of arginine for glycine at codon 185 of
Nramp2 has been shown to result in a near total loss ofcate the true iron stores, as is the case in patients with
liver diseases, during inflammation or cancer. Further the function of the Nramp2 protein in mk mice and
Belgrade (b) rats, resulting in microcytic anemia due toreasons for increased ferritin levels include smoking [85]
or the cross-reaction between ferritin and IgM in latex- defects in intestinal iron transport and erythroid iron
utilization [4].based immunoassays, as has been described in a renal
transplant patient with polyclonal hypergammaglobuli- 1. Gross CN, Irrinki A, Feder JN, Enns CA: Co-trafficking of HFE,
a nonclassical major histocompatibility complex class I protein, withnemia [94]. In cases with otherwise inexplicable in-
the transferrin receptor implies a role in intracellular iron regulation.creased serum ferritin concentrations, clinicians should
J Biol Chem 273:22068–22074, 1998
consider the rare syndromes of hereditary hyperferriti- 2. Kaltwasser JP, Gottschalk R. Seidl CH: Severe juvenile haemo-
chromatosis (JH) missing HFE gene variants: Implications for anemia [60, 68–74] or iron overload in Africans [53–59].
second gene locus leading to iron overload. Bt J Haematol 102:1111–
1112, 1998
3. Piperno A, Vergani A. Malosio I, Parma L, Fossati L, Ricci A,CONCLUSIONS
Bovo G, Boari G, Mancia G: Hepatic iron overload in patients with
chronic viral hepatitis: Role of HFE gene mutations. HepatologyKnowledge of the genetic basis of a variety of disorders
28:1105–1109, 1998of iron metabolism has created the possibility for pre- 4. Su MA, Trenor CC, Fleming JC, Fleming MD, Andrews NC:
symptomatic detection of a predisposition for iron over- The G185R mutation disrupts functions of the iron transporter
Nramp2. Blood 92:2157–2163, 1998load and the identification of late-onset diseases such as
hemochromatosis. Routine screening has the potential
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